Insider Trading Alert - Cepheid And 4 Others Traded By Insiders

Friday, July 8, 2013, 142 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1.15 to $10,873,958.42.

Highlighted Stocks Traded by Insiders:

Cepheid (CPHD) - FREE Research Report

Miller Andrew who is EVP, CFO at CEPHEID INC bought 860 shares at $17.11 per share for a total value of $8,041.70 on July 3, 2013. Following this transaction, the EVP, CFO owned 1,015 shares meaning that the stake was boosted by 137.6% with the 860 share acquisition.

The shares most recently traded at $35.72, up $0.05, or 0.14% since the insider transaction. Historical insider transactions for Cepheid go as follows:

  • 4-Week # shares sold: 12,468
  • 12-Week # shares sold: 13,050
  • 24-Week # shares sold: 13,197

The average volume for Cepheid has been 485,000 shares per day over the past 30 days. Cepheid has a market cap of $2.3 billion and is part of the technology sector and electronics industry. Shares are up 1.06% year to date as of the close of trading on Friday.

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market; and for application in legacy non-clinical market. Currently there are 10 analysts that rate Cepheid a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CPHD - FREE

TheStreet Quant Ratings rates Cepheid as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Cepheid Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Bet on Animal Health By Investing in Idexx Laboratories, Analysts Say

Cepheid (CPHD) Stock Downgraded to 'Neutral' at Baird

Cepheid (CPHD) Stock Price Target Raised at Barclays on Danaher Deal

Abbott's Alere Pushback Could Color Future Dealmaking Efforts

Jim Cramer's 'Mad Money' Recap: These Stocks Will Rise, Whatever the Fed Does